[PDF] Top 20 Estudio de las redes sociales en Puerto Venecia
Has 10000 "Estudio de las redes sociales en Puerto Venecia" found on our website. Below are the top 20 most common "Estudio de las redes sociales en Puerto Venecia".
Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
... TRYPHAENA neoadjuvant trial also highlighted the lack of significant cardiac toxicities associated with dual pertuzumab and tras- tuzumab ...HER2 neoadjuvant treatments (18- versus 12-week cycle) may ... See full document
21
Cost utility analysis of adjuvant trastuzumab therapy for HER2 positive early stage breast cancer in the Philippines
... Breast cancer is currently the globally leading malig- nancy among women with about ...prevalent cancer among women and in both sexes, as well as the most common cause of cancer deaths among ... See full document
10
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
... of breast tumors and has been associated with poor ...both early and advanced breast ...in clinical studies. Pertuzumab in combination with trastuzumab and taxane is currently approved ... See full document
24
Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study
... spective clinical trials will be integral to the identification of biomarkers that predict metformin benefit and the evalu- ation of its efficacy as a potential cancer ...with early-stage ... See full document
240
Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals
... In addition, patients analyzed with the 21-gene RS assay corresponded to the entire BC incident population of the participating hospitals. However, the patient cohort presents a limitation. The testing criteria ... See full document
32
Intensity-modulated radiation therapy for early-stage breast cancer: is it ready for prime time?
... Whole breast external beam radiotherapy (WBEBRT) is commonly used as an essential arm in the treatment management of women with early-stage breast ...radiation therapy (IMRT) is an ... See full document
12
High Ki-67 and Vascular Endothelial Growth Factor (VEGF) Protein Expression as Negative Predictive Factor for Combined Neoadjuvant Chemotherapy in Young Age Stage III Breast Cancer
... Background: Breast cancer was, in general, a heterogeneous disease with diverse biological characteristics, types, subtypes and clinical ...individualized. Breast cancer in young ages, ... See full document
95
<p>Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis</p>
... in breast cancer is a preoperative treatment, which is initially applied locally to advanced tumors to downgrade primary tumor and regional lymph nodes and enable their removal by ...Currently, ... See full document
99
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
... the pertuzumab group and 3.7% in the placebo group). During targeted therapy alone, after ces- sation of chemotherapy, the incidence of grade 3 or higher diarrhea was ...the pertuzumab group and ... See full document
5
Precision medicine and personalized breast cancer: combination pertuzumab therapy
... targeted therapy in breast cancer. Pertuzumab, another humanized monoclonal antibody, binds to a different domain of HER2 and prevents the formation of HER2:HER3 dimers, which is the most ... See full document
19
Measuring decision quality: psychometric evaluation of a new instrument for breast cancer chemotherapy
... with early stage (I or II) breast cancer face a highly challenging decision – whether or not to undergo adjuvant ...after breast cancer, but it also poses risks of serious ... See full document
12
18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2- positive breast cancer
... III) breast cancer who accepted neoadjuvant ...therapy. Clinical stage was determined according to the American Joint Committee on Cancer 6th ...T stage were ... See full document
54
Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
... We used two-dimensional echocardiography to monitor trastuzumab-related cardiotoxicity following the current clinical guidelines. This is a readily available cardiac imag- ing modality with low cost and is ... See full document
114
Neoadjuvant radiotherapy of early stage breast cancer and long term disease free survival
... of neoadjuvant RT may introduce concerns for subsequent lumpectomy, including skin burn and ...through neoadjuvant accelerated partial breast irradiation or stereotactic protocols ...with ... See full document
9
Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours
... of breast cancer patients who have oestrogen receptor (ER) alpha-positive tumours receive adjuvant oestrogen deprivation ...inhibitor therapy produces a 40% reduction in 10-year mortality ... See full document
14
Electronic brachytherapy as adjuvant therapy for early stage breast cancer: a retrospective analysis
... treated breast from the 12 patients were digitally contoured to identify the balloon applicator, the clinical target volume (CTV), ipsilateral breast tissue, heart, lungs, skin, and ...ipsilateral ... See full document
20
Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers
... for breast cancer. We have also initiated a clinical trial ...from breast tumor, peripheral blood, and imaging (Figure ...these clinical characteristics, imaging phenotypes, and genomic ... See full document
48
Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial
... positive breast cancer ...HER2-potitive breast cancer express p95HER2, which is resistant to ...targeted therapy, concurrently adding anthracycline may lead to additional benefit in our ... See full document
167
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
... with pertuzumab and chemotherapy improves survival in patients with HER2- positive metastatic breast cancer (BC) [1, ...of pertuzumab to trastuzumab-based neoadjuvant chemotherapy (NAC) ... See full document
7
Neoadjuvant Stereotactic Ablative Radiotherapy To Treat Early Stage Breast Cancer Patients: The Role Of DCE-MRI
... a therapy and that other physiological e ff ects can lead to false as- sessment of progression [98, ...lung cancer, SABR treatment can lead to the development of pneumonitis and fibrosis which presents as ... See full document
12
Related subjects